



SmartPA Criteria Proposal

Drug/Drug Class:	Antiretroviral Therapy (ART) PDL Edit
First Implementation Date:	April 7, 2022
Revised Date:	September 1, 2022
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Human immunodeficiency virus (HIV) is a blood-borne virus that attacks the body’s immune system and, if left untreated, can lead to acquired immunodeficiency syndrome (AIDS). HIV is typically transmitted via sexual intercourse, sharing intravenous drug equipment, and mother-to-child transmission. The Centers for Disease Control and Prevention (CDC) classifies HIV infection into 3 stages: Stage 1 (Acute HIV Infection), Stage 2 (Chronic HIV Infection), and Stage 3 (AIDS). Signs and symptoms can present at any of the stages of HIV infection and may include fever, malaise, rash, lymphadenopathy, and severe infections and/or opportunistic malignancies. By the end of 2016, there were an estimated 1.1 million people aged 13 years and older infected with HIV in the United States (U.S.). This includes an estimated 162,500 people who were undiagnosed. According to the 2019 CDC HIV surveillance report, from 2015 to 2019 the annual number and rate of diagnoses of HIV infection in the U.S. decreased. In 2019, the overall rate of HIV infection was 11.1 per 100,000 population, which included 36,398 new diagnoses.

Antiretroviral therapy was first introduced in 1987 for the treatment of HIV infection. Treatment has drastically improved since and combination ART has greatly reduced HIV-associated morbidity and mortality. Patients currently living with HIV without other significant comorbidities and who are receiving treatment can have life expectancies approaching that of the general population. ART is also effective at preventing HIV transmission in patients who are at higher risk of being exposed to HIV through sexual contact or injection drug use. The U.S. Department of Health and Human Services (DHHS) published updated guidelines in 2019 which recommend combination regimens for people living with HIV infection.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:

Group A	
Preferred Agents	Non-Preferred Agents
<ul style="list-style-type: none"> • Biktarvy® • Odefsey® • Tivicay® • Tivicay PD® • Triumeq® 	
Group B	
Single Tablet Regimens (STR)	
Preferred Agents	Non-Preferred Agents
<ul style="list-style-type: none"> • Complera® • Delstrigo® • Dovato® • Efavirenz/Emtricitabine/Tenofovir disoproxil (gen Atripla®) • Genvoya® • Stribild® • Symfi® • Symfi Lo® 	<ul style="list-style-type: none"> • Abacavir/Lamivudine/Zidovudine (gen Trizivir®) • Atripla® • Efavirenz/Tenofovir disoproxil/Lamivudine (gen Symfi Lo®) • Efavirenz/Tenofovir disoproxil/Lamivudine (gen Symfi®) • Juluca® • Symtuza® • Trizivir®
Non-Single Tablet Regimens (Non-STR)	
Preferred Agents	Non-Preferred Agents
<ul style="list-style-type: none"> • Abacavir • Abacavir/Lamivudine (gen Epzicom®) • Atazanavir Caps • Edurant® • Efavirenz • Emtricitabine Caps • Emtriva® Soln • Evotaz® • Isentress® • Lamivudine • Lamivudine/Zidovudine (gen Combivir®) • Norvir® powder packet/solution • Pifeltro® • Prezcobix® • Prezista® • Ritonavir Tabs • Tenofovir Tabs • Tybost® • Viread® Pwd • Vocabria® 	<ul style="list-style-type: none"> • Aptivus® • Cabenuva® • Cimduo® • Combivir® • Crixivan® • Didanosine DR Caps • Emtriva® Caps • Epivir® • Epzicom® • Etravirine Tabs • Fosamprenavir Tabs • Fuzeon® • Intelence® • Invirase® • Kaletra® • Lexiva® • Lopinavir/Ritonavir (gen Kaletra®) • Maraviroc • Nevirapine • Norvir® Tabs • Rescriptor® • Retrovir® • Reyataz® • Rukobia® • Selzentry® • Stavudine Caps • Sustiva® • Temixys® • Trogarzo®

SmartPA PDL Proposal Form

© 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

	<ul style="list-style-type: none"> • Videx® • Viracept® • Viramune® • Viread® Tabs • Zerit® • Ziagen® • Zidovudine
Group C	
Preferred Agents	Non-Preferred Agents
<ul style="list-style-type: none"> • Emtricitabine/Tenofovir disoproxil (gen Truvada®) 	<ul style="list-style-type: none"> • Descovy® • Truvada®

- Type of Criteria:** Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit
- Data Sources:** Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Antiretroviral Therapy (ART) Agents
- Age range: All appropriate MO HealthNet participants

Approval Criteria

Initial Approval

- Participants will be able to access any antiretroviral drug for the treatment of HIV that they currently utilize and on which they are stable or that they have successfully utilized previously, excluding those agents in Group C. For more information on Group C non-preferred agents approval criteria please see below.
- Claims for an agent in Group A do not require prior authorization
- Claim is for an agent in Group B
 - For preferred agents: failure to achieve desired therapeutic outcomes with trial on 1 Group A agent
 - For non-preferred STR agents: failure to achieve desired therapeutic outcomes with trial on 1 Group A agent and 1 preferred Group B STR agent
 - For non-preferred non-STR agents: failure to achieve desired therapeutic outcomes with trial on 1 Group A agent and 1 preferred Group B agent
 - For liquid formulations of zidovudine, nevirapine, and lopinavir/ritonavir: participant is < 10 years of age
 - For Juluca: participant has documented diagnosis of chronic kidney disease stage 3, 4, or 5
 - For Cabenuva:
 - Participant is aged ≥ 12 years **AND**
 - Dosage regimen is for every two-month administration **AND**
 - Documentation that participant is virologically suppressed (HIV-1 RNA < 50 copies/mL) **AND**
 - Documented compliance to oral ART regimen for at least 3 months **OR**
 - Documented inability to swallow tablets
 - For Viread: participant has documented diagnosis of hepatitis B infection.
- Claim is for an agent in Group C
 - Claim for generic Truvada does not require prior authorization
 - For brand Truvada: documented allergy to generic Truvada
 - For Descovy: documentation of medical necessity (examples include ADE/ADR to gen Truvada, renal insufficiency, or osteoporosis)
- Documented ADE/ADR to preferred agents **OR**

SmartPA PDL Proposal Form

© 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- Documented genotypic resistance test showing resistance to preferred agents

Continuation of Therapy

- Initial Prior Authorization for Cabenuva is 6 months, continued prior authorization will be for 12 months based on:
 - Documented adherence to Cabenuva therapy **AND**
 - Documented continued virologic suppression

Denial Criteria

- Lack of adequate trial on required preferred agents
- For Cabenuva:
 - History of prior virologic failure **OR**
 - Dosage regimen is for monthly administration
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
 MedWatch Form:

Progress Notes:
 Other:

Disposition of Edit

Denial: Exception code “0160” (PDL Edit)
 Rule Type: PDL

Default Approval Period

1 year

References

1. Evidence-Based Medicine and Fiscal Analysis: “Antiretroviral Agents – Therapeutic Class Review”, Conduent Business Services, L.L.C., Richmond, VA; November 2021.
2. Evidence-Based Medicine Analysis: “HIV Antiretrovirals”, UMKC-DIC; September 2021.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines on the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available at <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines>. Accessed November 2021.
4. IPD Analytics. Rx Insights: Infectious Disease. HIV – Update on Treatment Management. November 2019.
5. Centers for Disease Control and Prevention. HIV Surveillance Report, 2019; vol. 32. <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published May 2021. Accessed November 2021.
6. Gilroy, S. HIV Infection and AIDS. Medscape. [HIV Infection and AIDS: Practice Essentials, Background, Pathophysiology \(medscape.com\)](https://www.medscape.com/viewarticle/968443). Accessed November 2021.